Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
filingDate |
2018-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_579591167a9806742e1c55c9e3e08eeb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a3669e10a25e64267f400af0e6fc317 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c497a81890799f29df912b673461ed34 |
publicationDate |
2018-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2018136891-A1 |
titleOfInvention |
Treatment of cancers using anti-emp2 antibody and pd-1/pdl-1 pathway antagonist combination therapy |
abstract |
Provided herein are compositions and methods for the treatment of a cancer in a subject having such a cancer (e.g., a breast cancer). In particular, the compositions provided herein include an anti-EMP2 antibody and a PD-l/PD-Ll pathway antagonist. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3868784-A4 |
priorityDate |
2017-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |